Data on this page show the responses of pregnant individuals who received the Moderna COVID-19 vaccine and completed an AusVaxSafety survey sent on day 3 after vaccination. These data provide you with a profile of what to expect in the days following your Moderna COVID-19 vaccination and can assist when planning for your COVID-19 vaccination.

There are currently insufficient data to conduct meaningful analysis of dose 1 and dose 2 of the Moderna COVID-19 vaccine in pregnant individuals. This is because the Moderna COVID-19 vaccine was approved for use as a primary course in pregnant individuals only after the overwhelming majority of the adult population had already received the Pfizer COVID-19 vaccine as a primary course.

Have you been diagnosed with myocarditis following COVID-19 vaccination?

Enrol in the AusVaxSafety long-term follow-up program to help Australia better understand the long-term effects of myocarditis following COVID-19 vaccination.

Click here to enrol or learn more


AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.

Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here.

Links to further information on the expected profile for COVID-19 vaccines used in Australia are available below: 

AusVaxSafety will continue to closely monitor the safety data of all COVID-19 vaccines in use in Australia in conjunction with the TGA.

Last updated August 2022